Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: A meta-analysis and systematic review

European Heart Journal

Volumn 36, Issue 41, 2015, Pages 2780-2789

  Chatterjee, Neal A ^a   Roka, Attila ^a   Lubitz, Steven A ^a   Gold, Michael R ^b   Daubert, Claude ^c   Linde, Cecilia ^d   Steffel, Jan ^e   Singh, Jagmeet P ^a   Mela, Theofanie ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c RENNES UNIVERSITY HOSPITAL   (France)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Meta analysis; Resynchronization; Ventricular tachyarrhythmia

Indexed keywords

ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; DATA BASE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE FUNCTION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; META ANALYSIS; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK; SYSTEMATIC REVIEW; AGED; CONVALESCENCE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; STATISTICS AND NUMERICAL DATA; TACHYCARDIA, VENTRICULAR;

AGED; CARDIAC RESYNCHRONIZATION THERAPY; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HEART FAILURE; HUMANS; MALE; RECOVERY OF FUNCTION; STROKE VOLUME; TACHYCARDIA, VENTRICULAR; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84983175122     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv373     Document Type: Article

References (41)

1. Leyva F, Nisam S, Auricchio A. 20 years of cardiac resynchronization therapy. J Am Coll Cardiol 2014;64:1047-1058.
2. Dickstein K, Bogale N, Priori S, Auricchio A, Cleland JG, Gitt A, Limbourg T, Linde C, van Veldhuisen DJ, Brugada J. The European cardiac resynchronization therapy survey. Eur Heart J 2009;30:2450-2460.
3. Garcia-Lunar I, Castro-Urda V, Toquero-Ramos J, Mingo-Santos S, Monivas-Palomero V, Daniela Mitroi C, Sanchez-Garcia M, Perez-Pereira E, Delgado HE, Fernandez-Lozano I. Ventricular arrhythmias in super-responders to cardiac resynchronization therapy. Rev Esp Cardiol (Engl Ed) 2014;67:883-889.
4. Manfredi JA, Al-Khatib SM, Shaw LK, Thomas L, Fogel RI, Padanilam B, Rardon D, Vatthyam R, Gemma LW, Golden K, Prystowsky EN. Association between left ventricular ejection fraction post-cardiac resynchronization treatment and subsequent implantable cardioverter defibrillator therapy for sustained ventricular tachyar-rhythmias. Circ Arrhythm Electrophysiol 2013;6:257-264.
5. Ruwald MH, Solomon SD, Foster E, Kutyifa V, Ruwald AC, Sherazi S, McNitt S, Jons C, Moss AJ, Zareba W. Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: results from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) trial. Circulation 2014; 130:2278-2286.
6. Schaer BA, Osswald S, Di Valentino M, Soliman OI, Sticherling C, ten Cate FJ, Jordaens L, Theuns DA. Close connection between improvement in left ventricular function by cardiac resynchronization therapy and the incidence of arrhythmias in cardiac resynchronization therapy-defibrillator patients. Eur J Heart Fail 2010;12: 1325-1332.
7. Sebag FA, Lellouche N, Chen Z, Tritar A, O'Neill MD, Gill J, Wright M, Leclercq C, Rinaldi CA. Positive response to cardiac resynchronization therapy reduces arrhythmic events after elective generator change in patients with primary prevention CRT-D. J Cardiovasc Electrophysiol 2014;25:1368-1375.
8. Steffel J, Milosevic G, Hurlimann A, Krasniqi N, Namdar M, Ruschitzka F, Luscher TF, Duru F, Holzmeister J, Hurlimann D. Characteristics and long-term outcome of echocardiographic super-responders to cardiac resynchronisation therapy: 'real world' experience from a single tertiary care centre. Heart 2011; 97:1668-1674.
9. Van Boven N, Bogaard K, Ruiter J, Kimman G, Theuns D, Kardys I, Umans V. Functional response to cardiac resynchronization therapy is associated with improved clinical outcome and absence of appropriate shocks. J Cardiovasc Electrophysiol 2013; 24:316-322.
10. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, Cleland J, Deharo JC, Delgado V, Elliott PM, Gorenek B, Israel CW, Leclercq C, Linde C, Mont L, Padeletti L, Sutton R, Vardas PE. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace 2013;15:1070-1118.
11. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-2012.
12. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998;52:377-384.
13. Guevara JP, Berlin JA, Wolf FM. Meta-analytic methods for pooling rates when follow-up duration varies: a case study. BMC Med Res Methodol 2004;4:17.
14. Higgins J, Thompson S, Deeks J, Altman D. Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J Health Serv Res Policy 2002;7:51-61.
15. Sterne JA, Juni P, Schulz KF, Altman DG, Bartlett C, Egger M. Statistical methods for assessing the influence of study characteristics on treatment effects in 'meta-epidemiological' research. Stat Med 2002;21:1513-1524.
16. Lam SK, Owen A. Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials. BMJ 2007;335:925.
17. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-2150.
18. Saxon LA, Bristow MR, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, Feldman AM, Galle E, Ecklund F. Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. Circulation 2006;114: 2766-2772.
19. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J 2006;27:1928-1932.
20. Cha YM, Chareonthaitawee P, Dong YX, Kemp BJ, Oh JK, Miyazaki C, Hayes DL, Rea RF, Asirvatham SJ, Webster TL, Dalzell CM, Hodge DO, Herges RM, Yong YZ, Zhang Y, Chen PS. Cardiac sympathetic reserve and response to cardiac resynchro-nization therapy. Circ Heart Fail 2011;4:339-344.
21. Di Biase L, Gasparini M, Lunati M, Santini M, Landolina M, Boriani G, Curnis A, Bocchiardo M, Vincenti A, Denaro A, Valsecchi S, Natale A, Padeletti L. Antiar-rhythmic effect of reverse ventricular remodeling induced by cardiac resynchroni-zation therapy: the InSync ICD (Implantable Cardioverter-Defibrillator) Italian Registry. J Am Coll Cardiol 2008;52:1442-1449.
22. Eickholt C, Siekiera M, Kirmanoglou K, Rodenbeck A, Heussen N, Schauerte P, Lichtenberg A, Balzer J, Rassaf T, Perings S, Kelm M, Shin DI, Meyer C. Improvement of left ventricular function under cardiac resynchronization therapy goes along with a reduced incidence of ventricular arrhythmia. PloS One 2012;7: e48926.
23. Manne M, Rickard J, Varma N, Chung MK, Tchou P. Normalization of left ventricular ejection fraction after cardiac resynchronization therapy also normalizes survival. Pacing Clin Electrophysiol 2013;36:970-977.
24. Kandala J, Altman RK, Park MY, Singh JP. Clinical, laboratory, and pacing predictors of CRT response. J Cardiovasc Transl Res 2012;5:196-212.
25. Antonio N, Teixeira R, Coelho L, Lourenco C, Monteiro P, Ventura M, Cristovao J, Elvas L, Goncalves L, Providencia LA. Identification of 'super-responders' to cardiac resynchronization therapy: the importance of symptom duration and left ventricular geometry. Europace 2009;11:343-349.
26. Hsu JC, Solomon SD, Bourgoun M, McNitt S, Goldenberg I, Klein H, Moss AJ, Foster E. Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome: the MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy) study. J Am Coll Cardiol 2012;59:2366-2373.
27. Ghio S, Freemantle N, Scelsi L, Serio A, Magrini G, Pasotti M, Shankar A, Cleland JG, Tavazzi L. Long-term left ventricular reverse remodelling with cardiac resyn-chronization therapy: results from the CARE-HF trial. Eur J Heart Fail 2009;11: 480-488.
28. Kloppe A, Proclemer A, Arenal A, Lunati M, Martinez Ferrer JB, Hersi A, Gulaj M, Wijffels MC, Santi E, Manotta L, Mangoni L, Gasparini M. Efficacy of long detection interval implantable cardioverter-defibrillator settings in secondary prevention population: data from the Avoid Delivering Therapies for Nonsustained Arrhythmias in ICD Patients III (ADVANCE III) trial. Circulation 2014;130:308-314.
29. Costea A, Rardon DP, Padanilam BJ, Fogel RI, Prystowsky EN. Complications associated with generator replacement in response to device advisories. J Cardiovasc Electrophysiol 2008;19:266-269.
30. Kleemann T, Becker T, Doenges K, Vater M, Senges J, Schneider S, Saggau W, Weisse U, Seidl K. Annual rate of transvenous defibrillation lead defects in implan-table cardioverter-defibrillators over a period of.10 years. Circulation 2007;115: 2474-2480.
31. Yao G, Freemantle N, Calvert MJ, Bryan S, Daubert JC, Cleland JG. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implan-table cardioverter-defibrillator. Eur Heart J 2007;28:42-51.
32. Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, Reddy RK, Marchlinski FE, Yee R, Guarnieri T, Talajic M, Wilber DJ, Fishbein DP, Packer DL, Mark DB, Lee KL, Bardy GH. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 2008;359:1009-1017.
33. Zhan C, Baine WB, Sedrakyan A, Steiner C. Cardiac device implantation in the United States from 1997 through 2004: a population-based analysis. J Gen Intern Med 2008;23(Suppl 1):13-19.
34. Tung R, Zimetbaum P, Josephson ME. A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. J Am Coll Cardiol 2008;52:1111-1121.
35. Barsheshet A, Moss AJ, Huang DT, McNitt S, Zareba W, Goldenberg I. Applicability of a risk score for prediction of the long-term (8-year) benefit of the implantable cardioverter-defibrillator. J Am Coll Cardiol 2012;59:2075-2079.
36. Thijssen J, van Rees JB, Venlet J, Borleffs CJ, Hoke U, Putter H, van der Velde ET, van Erven L, Schalij MJ. The mode of death in implantable cardioverter-defibrillator and cardiac resynchronization therapy with defibrillator patients: results from routine clinical practice. Heart Rhythm 2012;9:1605-1612.
37. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA 3rd, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009;361:1329-1338.
38. Jolly S, Dorian P, Alter DA. The impact of implantable cardiac defibrillators for primary prophylaxis in the community: baseline risk and clinically meaningful benefits. J Eval Clin Pract 2006;12:190-195.
39. Russo AM, Stainback RF, Bailey SR, Epstein AE, Heidenreich PA, Jessup M, Kapa S, Kremers MS, Lindsay BD, Stevenson LW. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. Heart Rhythm 2013;10:e11-e58.
40. Gold MR, Daubert JC, Abraham WT, Hassager C, Dinerman JL, Hudnall JH, Cerkvenik J, Linde C. Implantable defibrillators improve survival in patients with mildly symptomatic heart failure receiving cardiac resynchronization therapy: a lysis of the long-term follow-up of remodeling in systolic left ventricular dysfu tion (REVERSE). Circ Arrhythm Electrophysiol 2013;6:1163-1168.
41. Morani G, Gasparini M, Zanon F, Casali E, Spotti A, Reggiani A, Bertagli Solimene F, Molon G, Accogli M, Tommasi C, Paoletti Perini A, Ciardiello Padeletti L. Cardiac resynchronization therapy-defibrillator improves long-t survival compared with cardiac resynchronization therapy-pacemaker in patie with a class IA indication for cardiac resynchronization therapy: data from the C tak Italian Registry. Europace 2013;15:1273-1279.